Endogenous Corticosteroid Derived Lipid Nanoparticles (Cortico LNPs) Enable Selective mRNA Delivery to the Spleen

🥈 Top 2% JournalJul 25, 2025Small (Weinheim an der Bergstrasse, Germany)

Natural Steroid-Based Lipid Particles Enable Targeted mRNA Delivery to the Spleen

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗

Abstract

Corticosterone- and progesterone-derived lipid nanoparticles achieve 97% and 99% spleen selectivity, respectively.

Endogenous corticosteroid-derived lipid nanoparticles redirect delivery from the liver to the spleen.
Multiple corticosteroids and their precursors are investigated for their roles in immune regulation and metabolism.
Corticosterone- and progesterone-LNPs show robust protein expression in vivo.
These lipid nanoparticles exhibit superior safety profiles compared to the clinical formulation SM-102.
Spleen-specific delivery may be mediated by the adsorption of β2-glycoprotein I on the LNP surface.
The approach is compatible with other clinically approved lipids, enhancing versatility in organ targeting.

AI simplified

Lipid nanoparticles (LNPs) have emerged as effective delivery vehicles for nucleic acids. However, conventional LNP formulations face several limitations, including poor endosomal escape and ApoE-mediated liver tropism. Here, a novel class of LNPs, endogenous corticosteroid-derived LNPs (cortico LNPs), is introduced in which the cholesterol component is replaced with endogenous corticosteroids, resulting in redirection from the liver to the spleen. Multiple corticosteroids and their precursors, including corticosterone, 11-deoxycortisol, 11-deoxycorticosterone, progesterone, 11β-hydroxyprogesterone, and pregnenolone, are investigated due to their critical roles in immune regulation, stress response, and metabolism. Among these, corticosterone- and progesterone-LNPs demonstrate robust protein expression in vivo with remarkable spleen selectivity of 97% and 99%, respectively. Additionally, these LNPs display superior safety profiles compared to the clinical SM-102 formulation. It is proposed that the adsorption of β2-glycoprotein I (β2-GPI) on the LNP surface mediates the spleen-specific delivery. Notably, this approach is also compatible with other clinically approved ionizable lipids, such as MC3 and ALC-0315, underscoring the versatility of corticosteroid modifications in optimizing organ tropism across different LNP platforms. These findings highlight the therapeutic potential of cortico LNPs to reprogram organ distribution and enhance gene targeting beyond the liver, representing an exciting advancement in the development of precision immunotherapy and gene therapy.

Full Text

Full text is available at the source.

View full text ↗

Abstract

Full Text

Related papers